Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Circle Internet Group shares plunged 20% after reports the Clarity Act may impose tighter stablecoin rules; USD Coin circulation is ~ $80 billion and yields ~3.5% on leading marketplaces, so curbs on promotional yields could materially reduce demand. Cathie Wood's Ark added to positions in Circle, Arcturus Therapeutics, and 10x Genomics, indicating opportunistic buying amid volatility. Arcturus faces steep revenue declines with analysts forecasting 2026 revenue roughly one-fifth of 2022's $206M but extended cash runway to Q2 2028 and reported positive Phase 2 development; 10x Genomics has grown revenue in seven of the past eight years but guidance points to a flat 2026.

Analysis

Regulatory risk is now the dominant lever for CRCL's valuation — a single legislative outcome can compress the addressable yield-sensitive float and shift distribution economics away from crypto-native marketplaces to regulated banking rails. Second-order winners are well-capitalized custodial banks and payment processors that can offer insured deposit-like products or white-label rails; second-order losers include margin-heavy exchanges and lending desks that monetize promotional rates.

For TXG, the near-term guide reset (flat medium-term top line) increases optionality on margin expansion and software/consumables attach rates rather than pure volume growth — that puts the pathway to upside in gross margin recovery and recurring revenue conversion over 12–24 months. Conversely, ARCT sits squarely in binary clinical-risk territory where a single readout or a financing event will re-rate the shares by 30–100% within quarters.

Timing matters: regulatory votes and committee markups operate on a 1–6 month cadence and can trigger immediate flow-driven dislocations in CRCL and its ecosystem; clinical readouts and data updates for ARCT are 3–18 month binary catalysts. The asymmetric trade set-up is to buy convex upside into secular themes (single-cell tools via TXG) while using short-duration, capital-light structures to express regulatory downside on CRCL and binary downside on ARCT — avoiding large outright directional exposure into noisy near-term windows.

Key Decisions for Investors

• CRCL: Buy 3-month ATM put protection sized to 1–2% of fund NAV (to cap regulatory-tail downside) and sell 6–9 month 10–20% OTM calls to finance ~50–75% of the premium. Timeframe: 1–3 months for legislative action; R/R: asymmetry — puts protect a larger equity position vs limited call cap.
• Pair trade (6–12 months): Long TXG (instrument or 12-month 25–35% OTM LEAP calls, 1–2% NAV) vs short ARCT (size-matched 3–6 month put or short equity 0.5–1% NAV). Rationale: secular, recurring-revenue upside in TXG vs binary clinical/financing downside in ARCT; target pair return 30–60% if thesis unfolds, max loss capped by options premium if using spreads.
• CRCL tactical short (event-driven, 1–3 months): Enter a directional put spread (buy 3-month ATM put, sell 3-month 20–30% OTM put) to monetize expected headline-driven skew. Risk: capped loss = net premium; reward: significant payoff if regulation causes >20% move lower.
• Contrarian re-entry plan (12 months): Accumulate incremental long CRCL exposure only after regulatory language is finalized or if shares overshoot by >30% on headline fear; size such purchases to 0.5–1% NAV tranches and hedge with 9–12 month protective puts for early payoff. Rationale: long-term network effects and custody partnerships could justify partial re-risking on clarity.